Real World Evidence Summit IMPACCT on June 09-11, 2025 in Amsterdam, Netherlands

As regulators and payers increasingly elevate the importance of RWE in submission requirements and with an explosion of datasets opening up in parallel with advancing AI, deep learning, and large language models transforming big data analysis, it has never been more critical to keep up with the matrix of country-specific regulatory nuances and industry case studies in optimizing integrated evidence plans, bullet-proofing data quality, and navigating vendor selection.

The 2nd IMPACCT Real World Evidence Summit Europe is the only industry meeting dedicated to uniting experts in RWE and Evidence Generation to consolidate, innovate and apply RWE across the drug development lifecycle, from external control arms to reimbursement.

With a tight focus on leveraging AI for both efficiency gains and big data analysis, the latest on DARWIN and using RWE to support regulatory decision-making, and creating a robust integrated evidence strategy, join 60+ industry pioneers from AstraZeneca, Pfizer, Novartis, Sanofi and more to collaboratively establish best practice and bridge the evidence gap between clinical research and practice, ensuring resilience and success in a dynamic landscape as a successful business partner.

URLs:

Tickets: https://go.evvnt.com/2850632-2?pid=10008

Brochure: https://go.evvnt.com/2850632-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Conference + 2 Workshops - Primary - OTD: EUR 3797.00,

Conference + 2 Workshops - Discounted - OTD : EUR 3097.00,

Conference + 2 Workshops - Vendor - OTD: EUR 4597.00,

Conference + 1 Workshop - Primary - OTD: EUR 3298.00,

Conference + 1 Workshop - Discounted - OTD : EUR 2798.00,

Conference + 1 Workshop - Vendor - OTD: EUR 3998.00,

Conference Only - Primary - OTD: EUR 2799.00,

Conference Only - Discounted - OTD : EUR 2399.00,

Conference Only - Vendor - OTD: EUR 3399.00

Speakers: Declan Summers, UK Head of RWE, Costello Medical, Alessandra Oortwijn, Global Head Evidence Generation, Alfasigma, Abir Tadmouri Sellier, Corporate RWE Director, Pierre Fabre Group, Galina Osina, Real World Evidence Lead, Former ROche, Amar Mehta, Senior Specialist - Real World Evidence and Epidemiology, H. Lundbeck A/S, Sebastian Kloss, Global Head RWE, Menarini Silicon Biosystems, Lene Hammer-Helmich, Director and Head of Real World Evidence and Epidemiology, H. Lundbeck A/S, Eva Laszlo, Netherlands Medical Director, Takeda, Pedro Ramos, CEO, Promptly Health, Lill-Brith von Arx, Director RWE Lead Northern Europe, Eli Lilly and Company, Katoo Muylle, RWE Manager, AstraZeneca, Onyinye Diribe, HEOR Real World Evidence Lead, Sanofi, Maurice Timmermans, Procurement Real World Evidence Generation and Dissemination Head, Astellas Pharma, Tina Roblek, Evidence Generation and Management Lead, Takeda, Swarna Khare, Director - Global Integrated Evidence Planning, Novartis, Or Shaked, Medical Research Lead, Briya, Luke McGuinness, Senior Manager, Alexion Pharmaceuticals